1.
ACS Med Chem Lett
; 12(11): 1733-1738, 2021 Nov 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34795861
RESUMO
Proteolysis targeting chimeras (PROTACs) hijacking the cereblon (CRBN) E3 ubiquitin ligase have emerged as a novel paradigm in drug development. Herein we found that linker attachment points of CRBN ligands highly affect their aqueous stability and neosubstrate degradation features. This work provides a blueprint for the assembly of future heterodimeric CRBN-based degraders with tailored properties.